More recently, the study of the gut–liver axis and, in particular, the farnesoid X receptor (FXR)–fibroblast growth factor (FGF)-19 signaling pathway and its role in bile acid metabolism, has led to a better understanding of PBC pathogenesis and the development of new targets for PBC treatment. The gene discussed is NR1H4; the disease is primary biliary cholangitis.